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LIM Domain Only 2 Regulates Endothelial Proliferation, Angiogenesis,
and Tissue Regeneration
Shu Meng, MD, PhD;* Gianfranco Matrone, PhD;* Jie Lv, PhD; Kaifu Chen, PhD; Wing Tak Wong, PhD; John P. Cooke, MD, PhD
Background-—LIM domain only 2 (LMO2, human gene) is a key transcription factor that regulates hematopoiesis and vascular
development. However, its role in adult endothelial function has been incompletely characterized.
Methods and Results-—In vitro loss- and gain-of-function studies on LMO2 were performed in human umbilical vein endothelial
cells with lentiviral overexpression or short hairpin RNA knockdown (KD) of LMO2, respectively. LMO2 KD significantly impaired
endothelial proliferation. LMO2 controls endothelial G1/S transition through transcriptional regulation of cyclin-dependent kinase
2 and 4 as determined by reverse transcription polymerase chain reaction (PCR), western blot, and chromatin immunoprecipitation,
and also influences the expression of Cyclin D1 and Cyclin A1. LMO2 KD also impaired angiogenesis by reducing transforming
growth factor-b (TGF-b) expression, whereas supplementation of exogenous TGF-b restored defective network formation in LMO2
KD human umbilical vein endothelial cells. In a zebrafish model of caudal fin regeneration, RT-PCR revealed that the lmo2 (zebrafish
gene) gene was upregulated at day 5 postresection. The KD of lmo2 by vivo-morpholino injections in adult Tg(fli1:egfp)y1 zebrafish
reduced 5-bromo-20-deoxyuridine incorporation in endothelial cells, impaired neoangiogenesis in the resected caudal fin, and
substantially delayed fin regeneration.
Conclusions-—The transcriptional factor LMO2 regulates endothelial proliferation and angiogenesis in vitro. Furthermore, LMO2
is required for angiogenesis and tissue healing in vivo. Thus, LMO2 is a critical determinant of vascular and tissue regeneration.
( J Am Heart Assoc. 2016;5: e004117 doi:10.1161/JAHA.116.004117)
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L IM domain only 2 (LMO2, human gene) is a criticaltranscription factor for initiation of yolk sac and definitive
hematopoiesis.1 The homozygous LMO2 null mutation leads to
failure of yolk sac erythropoiesis and embryonic lethality around
E10.5 in mice.1 LMO2 overexpression (OE) impedes the
differentiation of T progenitor cells, and aberrant activation of
LMO2 by chromosomal translocations contributes to T-cell
acute lymphoblastic leukemia in human.2,3 As a transcription
factor, LMO2 does not directly bind DNA, but instead forms a
DNA-binding complex with its two LIM–zinc-finger-like protein
interaction modules.4 LMO2 interacts with GATA-1, TAL1, E2A,
and Ldb1/NL1 to form a DNA-binding complex that recognizes
a bipartite DNA motif comprising an E-box, CAGGTG followed
9 bp downstream by a GATA site.5
In addition, LMO2 plays an essential role in embryonic
angiogenesis.4 In fact, Lmo2 (mouse gene) null embryonic
stem cells in mouse chimeras showed marked disorganization
of the vascular system.4 Lmo2 knockdown (KD) by mor-
pholino (Mo) decreases the number of intersomitic vessel
sprouts and axial vessel formation in zebrafish embryos.6 In
endothelial cells (ECs), Fli1, Elf1, and Ets1 regulate LMO2
gene expression through direct binding to its proximal
promoter.7 Unlike other transcription factors crucial for
endothelial lineage development such as ETV2, LMO2 remains
highly expressed in adult ECs, suggesting a key role for this
transcription factor in adult EC function.
LMO2 has been suggested to play an important role in tumor
angiogenesis.8 Indeed, it is a robust marker of endothelium in
vascular neoplasms9 such as infantile hemangioma.10 In the
EAhy926 cell line, an immortalized EC line, OE of LMO2
promotes angiogenesis and cell proliferation.10 However, it is
unclear how LMO2 controls proliferation in the immortalized EC
line, nor is it known whether normal adult endothelial function
and vascular homeostasis are so regulated.
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To assess the role of LMO2 in adult EC function, we
performed in vitro loss- and gain-of function experiments of
LMO2 in human umbilical vein ECs (HUVECs) to assess major
aspects of endothelial function such as proliferation, network
formation, acetylated-low density lipoprotein (acLDL) uptake,
NO production, and cell surface marker expression. We
further screened and identified the key molecular targets of
LMO2, cyclin-dependent kinase (CDK) 2 and CDK4, and
related cyclins involved in endothelial proliferation and
transforming growth factor-b (TGF-b1)–promoted angiogene-
sis. We examined the role of LMO2 in vivo in a caudal fin
resection model in adult zebrafish. Our studies suggest that




All chemicals were purchased from Sigma-Aldrich (St. Louis,
MO) unless otherwise stated. EGM-2 medium and bullet kit
was from Lonza (Walkersville, MD). Angiogenesis RT Profiler
PCR Array and chromatin immunoprecipitation (ChIP) poly-
merase chain reaction (PCR) primers were from Qiagen
(Valencia, CA). TGF-b ELISA kits were from R&D Systems
(Minneapolis, MN). Taqman primers, cell proliferation kit,
AF594-conjugated acLDL, CellTracker Red, and Griess kit was
from Invitrogen (Carlsbad, CA). PE-human CD31 antibody and
APC-human CD144 antibody was from BD Biosciences (San
Jose, CA). ChIP kit was from Cell Signaling Technology
(Beverly, MA). Anti-human LMO2 antibody (clone SP51) was
purchased from Spring Bioscience (Pleasanton, CA). Cyclin
D1, p21, and horseradish peroxidase (HRP)–conjugated goat
anti-mouse/rabbit antibodies were from Santa Cruz Biotech-
nology Inc (Santa Cruz, CA). Cyclin A, Cyclin E, CDK2, and
CDK4 antibodies were from Millipore (Billerica, MA). b-Tubulin
antibody and anti-zebrafish lmo2 (zebrafish gene) antibody
was from Abcam (Cambridge, UK). Lentiviral particles of
control (CT) short hairpin RNA (shRNA) and LMO2 shRNA
were from Santa Cruz Biotechnology Inc. CT noncoding and
LMO2 open reading frame (ORF) OE lentiviral particles were
from Applied Biological Materials Inc (Richmond, BC, Canada).
Zebrafish Husbandry
Tg(fli1:egfp)y1 fish were raised according to standard proce-
dures11 and kept at 28°C under a 14/10-hour light/dark
cycle and fed with dry meal (Gemma Micro) twice per day.
Animals were housed and all experiments were carried out in
accordance with the recommendations of the Institutional
Animal Care and Use Committee. All surgery procedures were
performed under anesthesia.
Stable Cell Generation
HUVEC were cultured in EBM-2 basal medium supplemented
with EGM-2 bullet kits. HUVECs at passage 4 were grown to
60% confluence before infection with lentiviral particles
containing shRNA targeting LMO2 or ORF of LMO2. Scramble
shRNA containing virus or virus without LMO2 ORF were used
as controls. Stable KD or OE of LMO2 was obtained by
puromycin (1 lg/mL) selection for consecutive 14 days after
viral infection. LMO2 KD or OE was confirmed by gene
expression and protein level analysis.
Protein Extraction and Western Blot Analysis
Cultured cells or zebrafish tissue samples were collected and
solubilized in RIPA buffer (25 mmol/L Tris-HCl pH 7.6,
150 mmol/L NaCl, 1% NP-40, 1% sodium deoxycholate, and
0.1% SDS) supplemented with protease inhibitor cocktail.
Protein concentration was measured using BCA assay.
Samples (containing 50–100 lg protein) were subjected to
polyacrylamide gel electrophoresis (4–12% gradient) and
transferred onto nitrocellulose membranes. Blots were
stained with 1% Ponceau S for loading controls. Blots were
then blocked with 5% nonfat milk in PBST (PBS+0.1% Tween)
for 1 hour at room temperature and probed with primary
antibody overnight at 4°C. They were then washed 4 times
with PBST for 10 minutes. HRP-conjugated goat anti-mouse
or rabbit antibodies were incubated for 1 hour at room
temperature. Blots were washed 4 times with PBST for
10 minutes. Antigen-antibody complexes were then detected
by exposure in FluorChem M system from ProteinSimple (San
Jose, CA). b-tubulin was used as loading control.
RNA Extraction and RT-PCR
mRNA was extracted from cultured cells or homogenized
zebrafish caudal fins using column purification.12 The mRNA
was reverse transcribed into cDNA. Taqman primers targeting
specific genes were then used for real-time PCR (RT-PCR;
QuantStudio Real-Time PCR System, Life Technologies,
Carlsbad, CA). 18S was used as an internal control for
HUVEC studies and b-actin was used as an internal control for
zebrafish studies. Angiogenesis RT Profiler PCR Array was
performed according to the manufacturer’s manual.
Endothelial Proliferation Assay, Network
Formation Assay, and Griess Assay
Cell proliferation was examined by proliferation assay.
HUVECs were seeded at the same starting number 59104
cells in EGM-2 medium and counted and subcultured every
other day for 4 days. Angiogenesis was examined by matrigel
DOI: 10.1161/JAHA.116.004117 Journal of the American Heart Association 2


















 http://ahajournals.org by on M
arch 16, 2020
network formation assay. Briefly, 24-well plates were coated
with Matrigel 300 lL (BD Biosciences), and incubated at 37°C
for 30 minutes. In each well, 79104 cells in 500 lL EGM-2
medium was seeded. After 16 hours, cells were stained with
CellTracker Red 5 lmol/L for 30 minutes and visualized
under the fluorescence microscope. Griess assay was used
for NO measurement based on the manufacturer’s manual.
ELISA Assay
TGF-b1 ELISA assay was performed following the manufac-
turer’s manual.
ChIP-PCR Assay
ChIP assay was performed following the manufacturer’s
manual. Briefly, DNA and protein were crosslinked by 1%
formaldehyde. Chromatin was isolated and digested with
micrococcal nuclease. The DNA-protein complex was then
precipitated with control IgG or antibodies against LMO2
overnight at 4°C and protein A/G–conjugated magnetic beads
for 1 hour. Cross-links were reversed. The extracted DNA was
used as a template for PCR amplification of the targeted
promoter region. The putative LMO2 complex binding sites
were predicted using the DECODE (Decipherment of DNA
Elements) database.
Vivo-Mo Injection in Zebrafish
Suppression of lmo2 transcription factor was achieved by
using antisense vivo-Mo 50-GTAGAAGCCATTTTCAATATGATTC-
30 (Gene Tools LLC, Philomath, OR) targeting the LMO2 mRNA
translation initiation site. Vivo-Mo is made by covalently
binding a standard Mo to a synthetic scaffold containing
guanidinium head groups as a delivery moiety.13 An antisense
vivo-Mo that targets human b-globin intron mutation 50-CC
TCTTACCTCATTACAATTTATA-3 was used as control. Vivo-Mo
was injected into the retro-orbital vein, as previously
described.14 Briefly, zebrafish were anesthetized in tricaine
0.05 mg/mL, and 2 lL of 0.1 mmol/L vivo-Mo solution was
loaded in a glass capillary and injected with a standard
microinjector (IM300 Microinjector; Narishige, Tokyo, Japan)
on days 0, 2, 4, 6, 8, 10, 12, and 14.
BrdU Incorporation in Zebrafish
To label proliferating cells, a dose of 5 lL of 5-bromo-20-
deoxyuridine (BrdU; 10 mmol/L in PBS) was injected into the
retro-orbital vein at days 11 and 13 after the day 0 injection of
vivo-MO. At day 15, fish were euthanized for enzymatic
digestion in PBS containing trypsin 0.4%, 1 mmol/L EDTA,
and collagenase P 0.05 mg/mL, and incubated for
45 minutes at 28.5°C with pipetting every 5 to 10 minutes
to obtain single-cell suspension for fluorescence-activated cell
sorter (FACS) analysis.
Caudal Fin Resection and Regeneration
Caudal fin resection in adult fishes was performed with sterile
razor blades at day 4 after the day 0 injection of vivo-Mo and
allowed to regenerate. Total regeneration was measured as
previously described.15 Briefly, fin images were collected
before amputation and time points after amputation. The new
tissue area (in pixels) of the caudal fin from the new distal fin
edge to the amputation plane was quantified in each fish up to
5 days postresection using Image J software. The percentage
of regeneration for each fin at each time point was defined as
percentage of regeneration=1009 (regenerated tissue area/
original fin area amputated).
FACS Analysis
HUVECs were washed with PBS and trypsinized to generate
single-cell suspension. For cell surface marker detection,
single-cell suspension cells were stained with indicated
antibody. For cell cycle analysis, single-cell suspension was
fixed with 70% EtOH at 4°C overnight. Cells were then stained
using propidium iodide (PI)/RNase buffer for 30 minutes and
immediately run on a BD LSR II machine (BD Biosciences).
BrdU incorporation assay in zebrafish was performed as
previously described.16 Data were analyzed by FlowJo
software (FlowJo, LLC, Ashland, OR). Cell cycle distribution
was analyzed using the cell cycle package of FlowJo.
Data Analysis
Statistical analysis was performed with Prism 7 software
(GraphPad Software, Inc, La Jolla, CA). Results were expressed
as meanSEM. The Shapiro-Wilk test was used to confirm the
null hypothesis that the data follow a normal distribution.
Statistical comparisons between the two groups were then
performed via Student t test, and one-way ANOVA test was
used to analyze multiple groups. Bonferroni corrections test
was applied for multiple comparisons. P<0.05 was considered
significant.
Results
Generation of LMO2 KD HUVECs and LMO2 OE
HUVECs
A stable line of LMO2 KD HUVECs was generated by
infection with lentiviral particles containing shRNA targeting
LMO2 followed by puromycin selection. A CT HUVEC line
DOI: 10.1161/JAHA.116.004117 Journal of the American Heart Association 3
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was generated using lentiviral scramble shRNA. Compared
with CT cells, the LMO2 KD cells exhibited a 70% decrease
in LMO2 gene expression detected by RT-PCR (Figure 1A)
and an 80% reduction in protein level by Western blot
(Figure 1B). The morphology of LMO2 KD cells was similar
to CT (Figure S1). A stable line of HUVECs overexpressing
LMO2 was generated by lentiviral particles encoding the ORF
of LMO2 followed by puromycin selection. The CT HUVEC
line was generated using lentiviral particles without an LMO2
ORF. Compared with CT cells, the LMO2 OE stable cells had
8-fold increases in LMO2 gene expression detected by RT-
PCR (Figure 1C) and 7-fold increases in protein level by
Western blot (Figure 1D).
LMO2 KD Hindered G1/S Transition and Reduced
Proliferation
Cell growth was attenuated in the LMO2 KD as shown by
total cell numbers counted every other day for 4 days
(Figure 2A). This effect was likely due to an impairment of
cell proliferation, as cell cycle analysis by PI staining and
FACS revealed that the fraction of cells in S phase was
decreased (4.5% versus 9% in CT) and that in G1 phase was
slightly increased (Figure 2B and 2C), indicating an impair-
ment of G1/S transition. Further examination of G1/S
transition-related cell cycle genes by Western blot showed
decreased levels of CDK4, CDK2, Cyclin D1, Cyclin A1, while
Cyclin E and p21 expression were not significantly changed
(Figure 2D). ENCODE database prediction suggests that both
the CCGATAACGG region starting at +232 of CDK4 (Gene
ID: 1019) and the CCCTCAGGTGGTG region starting at
+2700 of CDK2 (Gene ID: 1017) could be potential LMO2
complex binding sites. ChIP assays confirmed that
LMO2 complex binds to both regions (Figure 2E and 2F).
In LMO2 KD HUVECs, LMO2 complex binding is reduced in
the CDK2 gene (by 50%; Figure 2E) and in the CDK4 gene
(by 75%; Figure 2F) consistent with a partial KD of LMO2
and downregulated gene expression of CDK2 and CDK4,
respectively.
LMO2 OE Increased G1/S Transition but Not
Proliferation
Cell cycle analysis showed that the fraction of cells in S phase
were increased (14.7% versus 7.9% CT) and that in G1 phase
decreased in LMO2 OE condition (Figure 3A and 3B).
However, cell proliferation was not changed by LMO2 OE
(Figure S2). Following LMO2 OE, Cyclin D1 mRNA level was
increased, whereas CDK2 and CDK4 mRNA levels remained
stable (Figure 3C). Interestingly, LMO2 OE increased only
Cyclin D1 and Cyclin A1 protein levels but not that of CDK2,
CDK4, Cyclin E, or p21 (Figure 3D).
LMO2 KD Impaired Endothelial Network
Formation: Role of TGF-b1
The LMO2 KD impaired endothelial network formation in
matrigel (Figure 4A). Further analysis of 84 angiogenesis-
related genes using the Qiagen Angiogenesis RT Profiler PCR
Array revealed that there was a substantial reduction in the
expression of core angiogenesis genes (33 of 84; Figure 4B) in
the LMO2 KD cells. Among them, TGF-b1 promoter region is
predicted to have LMO2 complex binding sites, indicating that it
could be a direct transcriptional target of LMO2. We confirmed
by RT-PCR (Figure 4C) and ELISA (Figure 4D) that TGF-b1 was
downregulated in LMO2KD cells. To determine the contribution
of TGF-b downregulation to impaired angiogenic processes in
LMO2 KD cells, we determined whether network formation
could be rescued by TGF-b. Indeed, supplementation of the
HUVEC LMO2 KD with exogenous TGF-b restored defective
network formation (Figure 4F). ENCODE database prediction
suggests that two regions on TGF-b1 (Gene ID: 7040) promoter
Figure 1. Generation of LMO2 knockdown (KD) or overex-
pressing cells. Human umbilical vein endothelial cells (HUVECs)
passage 4 (P4) were infected with lentiviral scramble short
hairpin RNA (shRNA) virus or LMO2 shRNA virus and selected
with puromycin (1 lg/mL) for 14 consecutive days to generate
stable KD cells. HUVECs P4 were infected with lentiviral particles
encoding LMO2 open reading frame (ORF) or virus without the
ORF and selected with puromycin to generate stable overexpres-
sion (OE) or control (CT) cell lines. A, reverse transcription
polymerase chain reaction (RT-PCR) examination of LMO2 mRNA
level of KD cells. B, Western blot examination of LMO2 protein
level in KD cells. C, RT-PCR examination of LMO2 mRNA level
in OE cells. D, Western blot examination of LMO2 protein level in
OE cells. Data are presented as meanSEM (n=3). *P<0.05 vs
CT.
DOI: 10.1161/JAHA.116.004117 Journal of the American Heart Association 4
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could potentially have LMO2 complex binding. One region,
CCGCAGCTGCTGC, starts at the proximal –901 position and
the other region, CAGATAGGGG, starts at the distal –4030
position. The ChIP assay revealed that LMO2 complex binds to
both regions (Figure 4G), confirming that TGF-b1 is a direct
transcriptional target of LMO2. Interestingly, in LMO2 KO cells,
the decreased binding of LMO2 complex was only observed in
the proximal –901 binding site, suggesting that this binding site
is more sensitive to LMO2 downregulation. Notably, OE of
LMO2 did not further increase TGF-b1 level, probably because
LMO2 binding to DNA involves the participation of other
components of the binding complex (Figure 4E). This explana-
tion is consistent with the observation that LMO2 OE did not
further promote endothelial network formation (Figure S3).
Figure 2. LMO2 knockdown (KD) reduced cell proliferation and hindered G1/S transition.
A, Cell growth curve. B, Cell cycle analysis by propidium iodide (PI) staining. C,
Quantification of cell fractions in G1, S, and G2/M phases. D, Western blot examination of
G1/S transition-related genes. E and F, chromatin immunoprecipitation polymerase chain
reaction analysis of LMO2 complex binding to CDK2 gene (+2700) and CDK4 gene (+232)
in both control (CT) and LMO2 KD cells. Data are presented as meanSEM (n=3). *P<0.05
vs CT.
DOI: 10.1161/JAHA.116.004117 Journal of the American Heart Association 5
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LMO2 KD Did Not Cause Global Loss of
Endothelial Function
Because the LMO2 KD caused a severe impairment in
angiogenic processes, we assessed other basic functions of
ECs after LMO2 KD. We assessed the expression of
endothelial surface markers, the uptake of acLDL, and the
elaboration of NO. Compared with CT cells, LMO2 KD did not
significantly alter acLDL uptake, the expression of CD31 and
CD144 as assessed by FACS analysis, or the synthesis of NO
as assessed by Griess assay (Figure S4).
Upregulation of lmo2 Gene Expression during
Regeneration of the Caudal Fin
To test whether lmo2 is required for tissue regeneration, we
assessed the gene expression of lmo2 and another early
endothelial marker gene tie2 in caudal fin tissue at 0, 1, 2,
and 5 days after caudal fin resection (Figure 5A). We
observed that tie2 gene expression remained stable (Fig-
ure 5C) from day 0 to day 5 (at which time about 50% of
the caudal fin was regenerated). Conversely, lmo2 gene
expression level significantly increased by 50% at day 5
when about 50% of the caudal fin was regenerated
(Figure 5B).
Adult Endothelial Proliferation Was Impaired with
lmo2 KD
To test the hypothesis that LMO2 plays a key role in the
proliferation of adult ECs in vivo, we injected vivo-Mo
targeting lmo2 translation start site in adult Tg(fli1:egfp)y1
zebrafish (2.5 months old) and quantified cell proliferation by
BrdU incorporation (Figure 6A). The lmo2 vivo-Mo significantly
downregulated lmo2 expression compared with the CT group
injected with a vivo-Mo targeting human b-globin, as shown
by Western blot (Figure 6E). The BrdU incorporation rate of
GFP+ ECs was 13.7% in the CT vivo-Mo group, whereas it
decreased to 7.2% in the lmo2 vivo-Mo–injected group
(Figure 6B and 6D). In contrast, the BrdU incorporation rate
in GFP cells was similar between the CT vivo-Mo (1.77%) and
lmo2 vivo-Mo injection groups (1.85%) (Figure 6B and 6C).
Regeneration of the Vasculature and Parenchyma
Was Impaired with lmo2 KD
The caudal fin was resected at 4 days after the first vivo-Mo
injection and its regeneration was followed up to day 15
(Figure 7A). At day 1 and 2 postresection, the percentage of
fin regeneration was similar in lmo2 KD and CT fish (Figure 7A
and 7B). However, at 5 days postresection, the percentage of
Figure 3. LMO2 overexpression promoted endothelial G1/S transition. A, Cell cycle
analysis by propidium iodide (PI) staining. B, Quantification of cell fractions in G1, S, and
G2/M phases. C, mRNA level of G1/S-related genes. D, Western blot examination of G1/S-
related genes. Data are presented as meanSEM (n=3). *P<0.05 vs control (CT).
DOI: 10.1161/JAHA.116.004117 Journal of the American Heart Association 6
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caudal fin regeneration was only 28% in LMO2 KD fish
compared with 44% in CT fish (Figure 7A and 7B). Further-
more, neoangiogenesis was impaired as the regenerated
vasculature area was significantly smaller (0.47 mm2) in lmo2
KD fish compared with CTs (0.74 mm2) at day 5 postresection
(Figure 7C and 7D). Interestingly, the morphology of the
neovessels in the lmo2 KD fish were aberrant with tangled
vessel complexes (Figure 7C), in comparison to the standard
vascular branching observed in the CT fish.
Discussion
Transcriptional Factor LMO2
LMO2 is a key transcription factor that regulates hematopoi-
esis1 and embryonic vascular development.4 LMO2 is con-
sidered as an oncogene in T cells as aberrant activation of
LMO2 by chromosomal translocations contributes to T-cell
acute lymphoblastic leukemia in humans.2,3 Lmo2 transgenic
mice develop T-cell leukemia as Lmo2 OE impedes T-cell
differentiation.17–19 LMO2 expression in adult murine and
human ECs has been reported.4 However, the role of LMO2 in
adult angiogenesis has not been systematically studied. Our
studies indicate that LMO2 is a critical factor in adult
angiogenesis and endothelial proliferation, and in the
response to injury, as it mediates the vascular regeneration
required for tissue repair.
LMO2 and Adult Angiogenesis
To examine the role of LMO2 in endothelial function, we
generated stable LMO2 KD cells using lentiviral shRNA in
HUVECs. The LMO2 KD was associated with severely
impaired angiogenesis as assessed by endothelial network
Figure 4. LMO2 knockdown (KD) impaired endothelial network formation, which can be rescued by exogenous transforming growth factor-b1
(TGF-b1). A, Network formation of control (CT) and LMO2 KD human umbilical vein endothelial cells (HUVECs). B, List of downregulated genes
identified in LMO2 KD in comparison to CT HUVECs using angiogenesis polymerase chain reaction (PCR) array. C, Reverse transcription PCR (RT-
PCR) of TGF-b1. D, ELISA for TGF-b levels in culture medium of CT and LMO2 KD cells. E, RT-PCR of TGF-b1 in CT and LMO2 overexpression
HUVECs. F, Network formation of CT and LMO2 KD HUVECs with or without supplementation of TGF-b 10 ng/mL. G, Chromatin
immunoprecipitation PCR analysis of LMO2 complex binding to TGF-b1 promoter (–901 and –4030 region) in both CT and LMO2 KD cells. Data
are presented as meanSEM (n=3). *P<0.05 vs CT.
DOI: 10.1161/JAHA.116.004117 Journal of the American Heart Association 7
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formation. We hypothesized that LMO2 may modulate the
expression of genes involved in angiogenesis. Accordingly, we
used an angiogenesis PCR array for the network of core
angiogenic genes and found that almost half of these genes
(33 of 84), including TGF-b1, were downregulated more than
2-fold. TGF-b1 is the most downregulated angiogenic cytokine
detected in our experimental system. Further, ENCODE
database prediction suggests one proximal (starting at –
901) and one distal (starting at –4030) consensus sequence
in the TGF-b1 promoter, which was confirmed by our ChIP
assays. TGF-b is an angiogenic cytokine that regulates
physiological and tumor angiogenesis.20,21 We found that
supplementation of TGF-b could rescue the impaired network
formation in the LMO2 KD, indicating that TGF-b is a critical
mediator of the angiogenic effects of LMO2. Subsequently, we
used ChIP analysis to confirm that LMO2 binds to both the
proximal and distal sites in the TGF-b1 promoter. Notably, the
proximal binding site seems to be more sensitive to a reduced
level of LMO2. We further confirmed that KD of LMO2 reduces
TGF-b1 gene expression.
Additional analysis (Data S1) using the Gene Expression
Omnibus (GEO) database ChIP-seq data indicates that the
LMO2 transcriptional complex may bind to more than 1 000
gene promoters in murine hemogenic endothelium22 and
mouse hematopoietic progenitor cells (Figure S5A). Among
these genes, only 627 Lmo2 downstream genes are identified
in both hemogenic endothelium and hematopoietic progenitor
cells, suggesting Lmo2 complex binding targets vary between
cell types. This observation might be explained by the
existence of differences between cell types in the prevalence
of LMO2 binding partners. Interestingly, five genes from the
GEO database that contain consensus sequences for the
LMO2 binding complex (Figure S5B), specifically COL18A1,
EPHB4, IGF1, PF4, and SPHK1, were also detected in our
angiogenesis PCR array. These genes could potentially be
direct transcriptional targets of LMO2 in adult ECs. Besides
direct transcriptional regulation, the mechanism of LMO2-
mediated indirect regulation requires future elucidation.
EC Proliferation is Regulated by LMO2
Our data further suggest that in ECs, LMO2 is a key regulator
of G1/S transition and cell proliferation. A recent bioinfor-
matics analysis23 predicted binding of the LMO2 complex to
promoter regions of cell cycle genes such as CDK2 and CDK4,
suggesting a potential regulation by LMO2 of cell cycle
progression. This prediction has not been experimentally
verified until now. We found that LMO2 KD in HUVECs
decreased cell proliferation (Figure 2A) and hindered the G1/
S transition (Figure 2B). Master genes that regulate G1/S
transition24 such as CDK2, CDK4, Cyclin D1, and Cyclin A1
were downregulated in LMO2 KD, while Cyclin E and p21 did
not change. Consistent with a previous bioinformatics
prediction report,23 our ChIP assay (Figure 2E and 2F)
confirms the binding of LMO2 complex to CDK2
(CCCTCAGGTGGTG site at +2700) and CDK4 (CCGATAACGG
at +232). We also confirmed that CDK4 is a direct transcrip-
tional target of LMO2 (Figure S5B).
The OE of LMO2 increased the expression of Cyclin D1 and
Cyclin A1 and was associated with an increased G1/S
transition. Since the LMO2 complex does not have a putative
Figure 5. lmo2 gene expression increased following caudal fin
resection and the regeneration process. A, To analyze changes in
gene expression in the regenerating caudal fin, the amputated
tissues from 15 fish were collected at day 0 (left panel) and
regenerating distal tissues were resected and collected at 1, 2, or
5 days after the original resection (n=5 for each time point) (right
panel, a fin at 2 days postresection). B, Gene expression of lmo2
in the regenerating fin. C, Gene expression of tie2 in the
regenerating fin. Data are presented as meanSEM (n=5).
*P<0.05 vs control.
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binding site for the promoter regions of Cyclin D1 and Cyclin
A1, its indirect regulation of these genes may be mediated by
an effect of LMO2 on other transcription factors. Although OE
of LMO2 in HUVECs promoted G1/S transition and increased
S phase (Figure 3A), it did not further promote proliferation
(Figure S2). Thus, while LMO2 is necessary for normal
proliferation of mature ECs, it is not sufficient to accelerate
their proliferation. This may be due to the fact that LMO2
binds to DNA with the help of other protein components of its
DNA binding complex. As LMO2 forms protein-protein inter-
actions with a variety of known binding partners,5,25,26 it may
also regulate gene expression through nontranscriptional
mechanisms.4,27,28 These other complex components may
become rate limiting in the setting of LMO2 OE. This
hypothesis would be consistent with the observation that
the expression of CDK2 and CDK4 was not increased after
LMO2 OE. In T cells where LMO2 is an oncogene, LMO2 OE
does not cause increased cycling but does cause
quiescence,29 suggesting that LMO2 functions differently in
different cell types.
Notably, LMO2 appears to have specificity for regulation of
angiogenic processes. We found that LMO2 KD did not cause
a global impairment of endothelial function as it did not alter
acLDL uptake, NO secretion, or the expression of specific EC
surface markers. To summarize, our in vitro studies indicate
that LMO2 is a critical and fairly specific regulator of
endothelial proliferation and angiogenesis. Accordingly, we
further investigated whether LMO2 is involved in the response
to injury as endothelial proliferation and angiogenesis are
required for tissue regeneration.
LMO2 Mediates Vascular and Tissue
Regeneration After Injury
As a model for vascular and tissue regeneration, we chose the
caudal fin resection model in zebrafish. Following amputation,
Figure 6. lmo2 knockdown (KD) by vivo-morpholino (Mo) in zebrafish reduced prolifer-
ating GFP+ cells. A, Adult Tg(fli1:egfp)y1 zebrafish fish (2.5 months old) received a retro-
orbital injection of PBS solution containing lmo2 or control (CT) vivo-Mo, then the caudal fin
was resected and injected with 5-bromo-20-deoxyuridine (BrdU), as shown in the diagram. B,
At day 15, whole fish were enzymatically digested and cell suspension was analyzed by flow
cytometry. Negative control was Wik (non-GFP) fish line not injected with BrdU. BrdU+ and
GFP+ events are shown in CT and lmo2 vivo-Mo–injected fish. C and D, Diagrams showing
the percentage of BrdU+GFP/GFP cells and BrdU+GFP+/GFP+ cells. E, Western blot of
lmo2 expression at day 10 in zebrafish without vivo-Mo injection or injected with CT or
lmo2 vivo-Mo injection. Data are presented as meanSEM (n=10). *P<0.05 vs CT.
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lineage-restricted mesenchymal progenitor cells form at the
wound edge, presumably via dedifferentiation of mature
somatic cells of the stump. ECs sprout into the avascular
area.27 Angiogenic cytokines such as vascular endothelial
growth factor have been shown to play a crucial role in this
process. Other major signaling pathways that regulate fin
regeneration include fibroblast growth factor, Hedgehog, bone
morphogenetic protein, retinoic acid, Wnt/b-catenin, insulin-
like growth factor, activin, Notch, mechanistic target of
rapamycin complex 1, and calcineurin.30,31
We first examined lmo2 gene expression during the
regeneration of the resected caudal fin in zebrafish. We
discovered that lmo2 gene expression is increased in
regenerating caudal fin at day 5 postresection (Figure 5B),
whereas the expression of tie2, an early endothelial marker32
known to promote vascular stability,33 was unchanged. This
Figure 7. lmo2 KD by vivo-morpholino (Mo) in zebrafish reduced caudal fin regeneration and impaired vascular regeneration. Adult Tg(fli1:
egfp)y1 zebrafish fish (2.5 months old) were injected with lmo2 or control (CT) vivo-Mo, then the caudal fin was resected and fin regeneration
was observed. A, Representative caudal fin images before resection and then at 0, 1, 2, and 5 days postresection (dpr) in fish injected with CT or
lmo2 vivo-Mo. B, Quantification of the regeneration. The whole area of the caudal fin at day 0 before resection and the new fin tissue area in
each fish from the new distal fin edge to the amputation plane were quantified at 0, 1, 2, and 5 dpr. Caudal fin regeneration for each fin at each
time point was defined as percentage of regeneration=1009 (regenerated tissue area/original fin area amputated). C, Representative image
showing decreased vasculature length in the regenerated fin in lmo2 KD fish compared with CT. The vertical white bar represents the length of
the regenerated vasculature. D, Quantification of the regenerated vascular area in CT at 5 dpr. Data are presented as meanSEM (n=10).
*P<0.05 vs CT.
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suggests that lmo2 upregulation is an early factor in vascular
and tissue regeneration.
To further confirm the role of lmo2 in tissue repair in vivo,
caudal fin regrowth was examined in adult zebrafish trans-
genic for fli1:egfp to mark ECs. In this model, 4% of the cells
of the fish are GFP+ cells. This finding agrees with the range in
humans, where ECs comprise about 3% to 6% of all cells in the
body.34 In these animals, we injected the lmo2 KD Mo
immediately prior to the caudal fin injury. We observed that
the percentage of proliferating ECs, as assessed by BrdU
incorporation, was drastically decreased by the Mo KD. By
contrast, the proliferation rate in residual non-ECs was not
affected. This finding suggests that lmo2 is necessary for
adult EC proliferation in vivo after an injury. Notably, the lmo2
KD also substantially limited tail regeneration. This observa-
tion would be consistent with impairment in neovasculariza-
tion, as it is critical to restore perfusion in the regeneration of
injured tissue.
Of note, the length and the morphology of the neovascu-
lature in the regenerating fin was affected in the lmo2 KD. In
addition to shorter branch lengths, the newly formed vessels
were also aberrant in the lmo2 KD, forming tangled vascular
complexes rather than the more linear morphology of the
neovessels forming during fin regeneration in the CT animals.
Vascular regeneration in the caudal fin was severely
impaired in lmo2 KD zebrafish, associated with a substantial
reduction in fin regeneration. Thus, LMO2 appears to be a
novel and potent player in vascular and tissue regeneration.
The translational relevance of this observation is that OE of
LMO2 might be useful in diseases characterized by ischemia
and impaired angiogenesis.5,25,26 Alternatively, LMO2 expres-
sion in the vasculature of some tumors8,9 suggests that
disruption of LMO2 regulation might be useful in disorders
characterized by pathological angiogenesis.35 To target T-cell
leukemia, antibodies or aptamers targeting LMO2 have been
developed.36,37 Although such agents may be effective anti-
tumor therapies, our studies suggest that such inhibitors
might adversely affect adult EC function and normal regen-
eration. Thus, careful examination of the vascular effects of
these inhibitors should be considered in their preclinical
development and clinical trials.
Conclusions
Our studies provide the first evidence that LMO2 is a critical
transcription factor that regulates adult EC proliferation and
angiogenesis. In addition, LMO2 appears to be critically
involved in the response to injury. By its regulation of vascular
regeneration, LMO2 is required for normal tissue repair. These
results indicate that LMO2 may be a good target for
therapeutic modulation in tissue regeneration.
Sources of Funding
This work was supported in part by grants to Dr Cooke from
the National Institutes of Health (U01 HL100397) and the
Cancer Prevention and Research Institute (RP150611). Dr





1. Warren AJ, Colledge WH, Carlton MB, Evans MJ, Smith AJ, Rabbitts TH. The
oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid
development. Cell. 1994;78:45–57.
2. Boehm T, Foroni L, Kaneko Y, Perutz M, Rabbitts T. The rhombotin family of
cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell
translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci
USA. 1991;88:4367–4371.
3. Royer-Pokora B, Loos U, Ludwig W. TTG-2, a new gene encoding a cysteine-
rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with
the t (11; 14)(p13; q11). Oncogene. 1991;6:1887–1893.
4. Yamada Y, Pannell R, Forster A, Rabbitts TH. The oncogenic LIM-only
transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in
mice. Proc Natl Acad Sci USA. 2000;97:320–324.
5. Wadman IA, Osada H, Gr€utz GG, Agulnick AD, Westphal H, Forster A, Rabbitts
TH. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid,
DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI
proteins. EMBO J. 1997;16:3145–3157.
6. Patterson LJ, Gering M, Patient R. Scl is required for dorsal aorta as well as
blood formation in zebrafish embryos. Blood. 2005;105:3502–3511.
7. Landry J-R, Kinston S, Knezevic K, Donaldson IJ, Green AR, G€ottgens B. Fli1,
Elf1, and Ets1 regulate the proximal promoter of the LMO2 gene in endothelial
cells. Blood. 2005;106:2680–2687.
8. Yamada Y, Pannell R, Forster A, Rabbitts TH. The LIM-domain protein Lmo2 is a
key regulator of tumour angiogenesis: a new anti-angiogenesis drug target.
Oncogene. 2002;21:1309–1315.
9. Gratzinger D, Zhao S, West R, Rouse RV, Vogel H, Gil EC, Levy R, Lossos IS,
Natkunam Y. The transcription factor LMO2 is a robust marker of vascular
endothelium and vascular neoplasms and selected other entities. Am J Clin
Pathol. 2009;131:264–278.
10. Sun ZJ, Cai Y, Chen G, Wang R, Jia J, Chen XM, Zheng LW, Zhao YF. LMO2
promotes angiogenesis probably by up-regulation of bFGF in endothelial cells:
an implication of its pathophysiological role in infantile haemangioma.
Histopathology. 2010;57:622–632.
11. Westerfield M. The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish
(Danio rerio). Eugene: University of Oregon Press; 2000.
12. Gu Q, Yang X, Lin L, Li S, Li Q, Zhong S, Peng J, Cui Z. Genetic ablation of
solute carrier family 7a3a leads to hepatic steatosis in zebrafish during fasting.
Hepatology. 2014;60:1929–1941.
13. Li YF, Morcos PA. Design and synthesis of dendritic molecular transporter that
achieves efficient in vivo delivery of morpholino antisense oligo. Bioconjug
Chem. 2008;19:1464–1470.
14. Pugach EK, Li P, White R, Zon L. Retro-orbital injection in adult zebrafish. J Vis
Exp. 2009. pii: 1645. doi: 10.3791/1645.
15. Petrie TA, Strand NS, Yang CT, Rabinowitz JS, Moon RT. Macrophages
modulate adult zebrafish tail fin regeneration. Development. 2014;141:2581–
2591.
16. Ergul AA, Halim D€O, Adams MM. Bromodeoxyuridine (BrdU) labeling
and immunohistochemical detection in adult zebrafish brain. Protoc Exch.
2013. doi:10.1038/protex.2013.087.
17. Larson RC, Osada H, Larson TA, Lavenir I, Rabbitts TH. The oncogenic LIM
protein Rbtn2 causes thymic developmental aberrations that precede
malignancy in transgenic mice. Oncogene. 1995;11:853–862.
18. Larson RC, Lavenir I, Larson TA, Baer R, Warren AJ, Wadman I, Nottage K,
Rabbitts TH. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters
DOI: 10.1161/JAHA.116.004117 Journal of the American Heart Association 11


















 http://ahajournals.org by on M
arch 16, 2020
thymocyte development and potentiates T cell tumorigenesis in transgenic
mice. EMBO J. 1996;15:1021–1027.
19. Neale GA, Rehg JE, Goorha RM. Disruption of T-cell differentiation precedes T-
cell tumor formation in LMO-2 (rhombotin-2) transgenic mice. Leukemia.
1997;11(suppl 3):289–290.
20. Pepper MS. Transforming growth factor-beta: vasculogenesis, angiogenesis,
and vessel wall integrity. Cytokine Growth Factor Rev. 1997;8:21–43.
21. Vi~nals F, Pouyssegur J. Transforming growth factor b1 (TGF-b1) pro-
motes endothelial cell survival during in vitro angiogenesis via an
autocrine mechanism implicating TGF-a signaling. Mol Cell Biol.
2001;21:7218–7230.
22. Goode DK, Obier N, Vijayabaskar MS, Lie ALM, Lilly AJ, Hannah R, Lichtinger
M, Batta K, Florkowska M, Patel R, Challinor M, Wallace K, Gilmour J, Assi SA,
Cauchy P, Hoogenkamp M, Westhead DR, Lacaud G, Kouskoff V, Gottgens B,
Bonifer C. Dynamic gene regulatory networks drive hematopoietic specifica-
tion and differentiation. Dev Cell. 2016;36:572–587.
23. Lee S-K, Choi YS, Cha J, Moon E-J, Lee S-W, Bae M-K, Sohn T-K, Won Y, Ma S,
Bae Kong E. Identification of novel anti-angiogenic factors by in silico
functional gene screening method. J Biotechnol. 2003;105:51–60.
24. Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle transcription during
G1 and S phases. Nat Rev Mol Cell Biol. 2013;14:518–528.
25. Schmeichel KL, Beckerle MC. The LIM domain is a modular protein-binding
interface. Cell. 1994;79:211–219.
26. Valge-Archer VE, Osada H, Warren AJ, Forster A, Li J, Baer R, Rabbitts TH. The
LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a
complex in erythroid cells. Proc Natl Acad Sci USA. 1994;91:8617–8621.
27. Xu C, Hasan SS, Schmidt I, Rocha SF, Pitulescu ME, Bussmann J, Meyen D, Raz
E, Adams RH, Siekmann AF. Arteries are formed by vein-derived endothelial tip
cells. Nat Commun. 2014;5:5758.
28. Coma S, Allard-Ratick M, Akino T, van Meeteren LA, Mammoto A, Klagsbrun M.
GATA2 and Lmo2 control angiogenesis and lymphangiogenesis via direct
transcriptional regulation of neuropilin-2. Angiogenesis. 2013;16:939–952.
29. Cleveland SM, Smith S, Tripathi R, Mathias EM, Goodings C, Elliott N, Peng D,
El-Rifai W, Yi D, Chen X, Li L, Mullighan C, Downing JR, Love P, Dave UP. Lmo2
induces hematopoietic stem cell-like features in T-cell progenitor cells prior to
leukemia. Stem Cells. 2013;31:882–894.
30. Wehner D, Weidinger G. Signaling networks organizing regenerative growth of
the zebrafish fin. Trends Genet. 2015;31:336–343.
31. Poss KD, Shen J, Nechiporuk A, McMahon G, Thisse B, Thisse C, Keating MT.
Roles for Fgf signaling during zebrafish fin regeneration. Dev Biol.
2000;222:347–358.
32. Foubert P, Matrone G, Souttou B, Lere-Dean C, Barateau V, Plouet J, Le
Ricousse-Roussanne S, Levy BI, Silvestre JS, Tobelem G. Coadministration of
endothelial and smooth muscle progenitor cells enhances the efficiency of
proangiogenic cell-based therapy. Circ Res. 2008;103:751–760.
33. von Tell D, Armulik A, Betsholtz C. Pericytes and vascular stability. Exp Cell
Res. 2006;312:623–629.
34. Bianconi E, Piovesan A, Facchin F, Beraudi A, Casadei R, Frabetti F, Vitale L,
Pelleri MC, Tassani S, Piva F, Perez-Amodio S, Strippoli P, Canaider S. An
estimation of the number of cells in the human body. Ann Hum Biol.
2013;40:463–471.
35. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653–660.
36. Nam CH, Lobato MN, Appert A, Drynan LF, Tanaka T, Rabbitts TH. An antibody
inhibitor of the LMO2-protein complex blocks its normal and tumorigenic
functions. Oncogene. 2008;27:4962–4968.
37. Appert A, Nam CH, Lobato N, Priego E, Miguel RN, Blundell T, Drynan L, Sewell
H, Tanaka T, Rabbitts T. Targeting LMO2 with a peptide aptamer establishes a
necessary function in overt T-cell neoplasia. Cancer Res. 2009;69:4784–4790.
DOI: 10.1161/JAHA.116.004117 Journal of the American Heart Association 12




















































ChIP-seq data analysis  
ChIP-seq data from Gene Expression Omnibus (GEO) database were analyzed to identify 
potential LMO2 direct transcriptional target. LMO2 ChIP-seq data of murine hemogenic 
endothelium (HE) (GEO accession no: GSM1692846) and of murine hematopoietic progenitor 
cells (HPC) (GSE69101), and input data of HE (GSM1692808) and of HPCs (GSM1692809) were 
used.  
For ChIP-seq analysis, Bowtie was used to map ChIP-Seq reads to the mouse reference genome 
version mm9, requiring single best match for each read across the genome. We used the 
function dpeak in DANPOS2 to calculate reads density from the mapped reads, normalized the 
total reads number of each ChIP-Seq sample to 25 million and defined enriched peaks with 
cutoff being Poisson test P value 1e-50. The extending length was set to 200bp and bin size to 
10bp in the calculation of reads density. We set the smooth width to 0bp to not use any 
smoothing step in the calculation. Input effect was subtracted from the ChIP-Seq data by 
DANPOS2. For reference gene set, we used the UCSC KnownGene provided at the Table 
Browser page of UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/hgTables), with the 
last updated date being 2011-03-02. To define LMO2 binding genes, we used the sub-command 
intersect of the bedtools suite to retrieve the subset of UCSC knownGenes transcripts with 
LMO2 binding regions overlapping with either their transcript bodies or the 5kb upstream 
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Figure S1-5 Legends 
Figure S1. Representative bright field image of CT and LMO2 KD HUVECs. 
Figure S2. LMO2 OE did not promote HUVEC proliferation. 
Figure S3. LMO2 OE did not promote network formation on matrigel. 
Figure S4. LMO2 knockdown in ECs did not interfere with ac-LDL uptake, NO secretion and cell 
surface marker levels.  A. FACS analysis of AF594-acLDL uptake in both CT and LMO2 KD 
HUVEC. B. Quantification of mean fluorescence intensity (MFI) of AF594-acLDL. C. NO 
production measurement using Griess assay. D. FACS analysis of PE-CD31 and APC-CD144. E&F. 
Quantification of MFI of CD31 and CD144. All data represented as mean ± S.E.M. (n=3). 
Figure S5. ChIP analysis of the LMO2 transcriptional targets in hemogenic endothelium and 
hematopoietic progenitor cells. A. LMO2 transcriptional targets. B. LMO2 transcriptional targets 
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